MX363265B - Forma cristalina i de ibrutinib. - Google Patents
Forma cristalina i de ibrutinib.Info
- Publication number
- MX363265B MX363265B MX2016006901A MX2016006901A MX363265B MX 363265 B MX363265 B MX 363265B MX 2016006901 A MX2016006901 A MX 2016006901A MX 2016006901 A MX2016006901 A MX 2016006901A MX 363265 B MX363265 B MX 363265B
- Authority
- MX
- Mexico
- Prior art keywords
- ibrutinib
- crystalline form
- preparation
- bruton
- btk
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Se revela la forma I cristalina de ibrutinib, procesos para su preparación, composiciones farmacéuticas que comprenden la forma nueva, y el uso de la forma I del ibrutinib para tratar o retrasar enfermedades o padecimientos relacionados con la actividad de las proteínas de tirosina cinasa de Bruton (BTK). La forma novedosa se caracteriza por la difracción en polvo con rayos X, calorimetría de barrido diferencial, y otras técnicas. Esta puede prepararse fácilmente y es adecuado su uso en la preparación de formas sólidas de dosificación.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310616065.4A CN103694241A (zh) | 2013-11-27 | 2013-11-27 | Pci-32765的新晶型a及其制备方法 |
CN201410542609.1A CN104327085B (zh) | 2013-11-27 | 2014-10-14 | Pci-32765的晶型a及其制备方法 |
PCT/US2014/067586 WO2015081180A1 (en) | 2013-11-27 | 2014-11-26 | Crystalline form i of ibrutinib |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2016006901A MX2016006901A (es) | 2016-10-28 |
MX363265B true MX363265B (es) | 2019-03-19 |
Family
ID=50355928
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016006901A MX363265B (es) | 2013-11-27 | 2014-11-26 | Forma cristalina i de ibrutinib. |
Country Status (14)
Country | Link |
---|---|
US (1) | US9751889B2 (es) |
EP (1) | EP3073999B1 (es) |
JP (1) | JP6483126B2 (es) |
CN (2) | CN103694241A (es) |
AU (1) | AU2014354728B2 (es) |
CA (1) | CA2932059C (es) |
DK (1) | DK3073999T3 (es) |
ES (1) | ES2684094T3 (es) |
HU (1) | HUE039718T2 (es) |
IL (1) | IL245865B (es) |
MX (1) | MX363265B (es) |
PL (1) | PL3073999T3 (es) |
PT (1) | PT3073999T (es) |
WO (1) | WO2015081180A1 (es) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3218491A1 (en) | 2012-06-04 | 2013-12-12 | Pharmacyclics Llc | Crystalline forms of a bruton's tyrosine kinase inhibitor |
AU2015237744A1 (en) | 2014-03-27 | 2016-09-15 | Wavelength Enterprises Ltd | Ibrutinib solid forms and production process therefor |
CN105085529A (zh) * | 2014-05-15 | 2015-11-25 | 广东东阳光药业有限公司 | 依鲁替尼新晶型及其制备方法 |
MX2017001671A (es) | 2014-08-07 | 2017-07-04 | Pharmacyclics Llc | Formulaciones novedosas de un inhibidor de la tirosina cinasa de bruton. |
US10035802B2 (en) | 2014-08-14 | 2018-07-31 | Teva Pharmaceuticals Usa, Inc. | Solid state forms of ibrutinib |
CZ201584A3 (cs) | 2015-02-09 | 2016-08-17 | Zentiva, K.S. | Sůl Ibrutinib sulfátu |
US10477780B2 (en) * | 2015-02-13 | 2019-11-19 | Hgci, Inc. | Multiple cell tray with media plugs |
BR122023020985A2 (pt) | 2015-03-03 | 2023-12-26 | Pharmacyclics Llc | Formulação de comprimido sólido de um inibidor de tirosina quinase de bruton |
JP6657269B2 (ja) * | 2015-03-20 | 2020-03-04 | クリスタル ファーマテック カンパニー、リミテッドCrystal Pharmatech Co., Ltd. | Pci―32765の結晶型aの調製方法 |
CN106153797B (zh) * | 2015-04-20 | 2017-08-29 | 北京睿创康泰医药研究院有限公司 | 一种依鲁替尼及依鲁替尼制剂有关物质分析方法 |
CN106153798B (zh) * | 2015-04-22 | 2017-08-29 | 北京睿创康泰医药研究院有限公司 | 一种用于分析依鲁替尼及依鲁替尼制剂有关物质的hplc方法以及这些杂质做参比标准的用途 |
KR20180040694A (ko) | 2015-08-19 | 2018-04-20 | 썬 파마슈티칼 인더스트리스 리미티드 | 이브루티닙의 결정형 및 그 제조 방법 |
ITUB20155616A1 (it) * | 2015-11-16 | 2017-05-16 | Laboratorio Chimico Int S P A | Procedimento per la preparazione della forma amorfa dell?ibrutinib e nuova forma cristallina. |
CN105294696A (zh) * | 2015-11-19 | 2016-02-03 | 上海创诺医药集团有限公司 | 依鲁替尼新晶型及其制备方法 |
CN106905320A (zh) * | 2015-12-23 | 2017-06-30 | 杭州容立医药科技有限公司 | 一种适合药用的依鲁替尼及其制剂 |
CN106995445B (zh) * | 2016-01-22 | 2021-08-03 | 山东新时代药业有限公司 | 一种布鲁顿酪氨酸激酶抑制剂晶型及其制备方法 |
CN107286163A (zh) * | 2016-03-30 | 2017-10-24 | 上海星泰医药科技有限公司 | 一种依鲁替尼的新晶型及其制备方法 |
CZ2016196A3 (cs) | 2016-04-06 | 2017-10-18 | Zentiva, K.S. | Pevné formy Ibrutinibu |
CZ2016276A3 (cs) | 2016-05-11 | 2017-11-22 | Zentiva, K.S. | Pevné formy volné báze ibrutinibu |
CN106117214A (zh) * | 2016-06-29 | 2016-11-16 | 上海创诺医药集团有限公司 | 依鲁替尼新晶型及其制备方法 |
CN106008529A (zh) * | 2016-08-08 | 2016-10-12 | 上海工程技术大学 | 一种依鲁替尼溶剂化物及其制备方法 |
US10183024B2 (en) | 2016-12-02 | 2019-01-22 | Apotex Inc. | Crystalline forms of ibrutinib |
WO2019070698A1 (en) | 2017-10-02 | 2019-04-11 | Johnson Matthey Public Limited Company | NEW FORMS OF IBRUTINIB |
CZ2017787A3 (cs) | 2017-12-08 | 2019-06-19 | Zentiva, K.S. | Farmaceutické kompozice obsahující ibrutinib |
WO2019195827A1 (en) | 2018-04-06 | 2019-10-10 | Johnson Matthey Public Limited Company | Novel form of ibrutinib |
US20220009929A1 (en) | 2018-05-02 | 2022-01-13 | Cipla Limited | Polymorphic forms of ibrutinib |
AU2019261986A1 (en) | 2018-05-03 | 2020-11-26 | Juno Therapeutics, Inc. | Combination therapy of a chimeric antigen receptor (CAR) T cell therapy and a kinase inhibitor |
EP3575300A1 (en) | 2018-05-31 | 2019-12-04 | Apotex Inc. | Novel crystalline forms of ibrutinib |
MX2020013321A (es) | 2018-06-19 | 2021-02-22 | Merck Patent Gmbh | Nuevas formas cristalinas de 1-(4-{[6-amino-5-(4-fenoxi-fenil)-pir imidin-4-ilamino]-metil}-4-fluoro-piperidin-1-il)-propenona, formas de sal de la misma y procesos de obtencion. |
CN111138436A (zh) * | 2018-11-04 | 2020-05-12 | 鲁南制药集团股份有限公司 | 伊布替尼晶型a单晶及其制备方法 |
US10688050B1 (en) | 2018-12-21 | 2020-06-23 | Synthon B.V. | Pharmaceutical composition comprising ibrutinib |
EP3669867A1 (en) | 2018-12-21 | 2020-06-24 | Synthon B.V. | Pharmaceutical composition comprising ibrutinib |
CN113214261A (zh) * | 2020-01-21 | 2021-08-06 | 尚科生物医药(上海)有限公司 | 一种依鲁替尼晶型a的纯化方法 |
WO2022260667A1 (en) | 2021-06-10 | 2022-12-15 | Hikma Pharmaceuticals Usa Inc. | Oral dosage forms of ibrutinib |
US11433072B1 (en) * | 2021-06-10 | 2022-09-06 | Hikma Pharmaceuticals USA, Inc. | Oral dosage forms of ibrutinib |
WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
WO2023242384A1 (en) | 2022-06-17 | 2023-12-21 | Krka, D.D., Novo Mesto | Crystalline form of ibrutinib |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009530342A (ja) * | 2006-03-20 | 2009-08-27 | エフ.ホフマン−ラ ロシュ アーゲー | Btkおよびsyk蛋白キナーゼを阻害する方法 |
DK2081435T3 (en) * | 2006-09-22 | 2016-08-15 | Pharmacyclics Llc | INHIBITORS OF BRUTON'S TYROSINKINASE |
KR20130099040A (ko) | 2010-08-10 | 2013-09-05 | 셀진 아빌로믹스 리서치, 인코포레이티드 | Btk 억제제의 베실레이트 염 |
WO2013155347A1 (en) | 2012-04-11 | 2013-10-17 | Izumi Raquel | Bruton's tyrosine kinase inhibitors for hematopoietic mobilization |
WO2013157021A1 (en) | 2012-04-20 | 2013-10-24 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
CA3218491A1 (en) | 2012-06-04 | 2013-12-12 | Pharmacyclics Llc | Crystalline forms of a bruton's tyrosine kinase inhibitor |
CN103121999A (zh) * | 2012-08-29 | 2013-05-29 | 苏州迪飞医药科技有限公司 | 一种酪氨酸激酶抑制剂pci-32765的合成方法 |
CN103142601A (zh) * | 2013-03-13 | 2013-06-12 | 杭州雷索药业有限公司 | Pci-32765在制备抗血管生成类药物中的应用 |
-
2013
- 2013-11-27 CN CN201310616065.4A patent/CN103694241A/zh active Pending
-
2014
- 2014-10-14 CN CN201410542609.1A patent/CN104327085B/zh active Active
- 2014-11-26 PL PL14866302T patent/PL3073999T3/pl unknown
- 2014-11-26 PT PT14866302T patent/PT3073999T/pt unknown
- 2014-11-26 CA CA2932059A patent/CA2932059C/en active Active
- 2014-11-26 US US15/100,247 patent/US9751889B2/en active Active
- 2014-11-26 JP JP2016535162A patent/JP6483126B2/ja active Active
- 2014-11-26 DK DK14866302.4T patent/DK3073999T3/en active
- 2014-11-26 HU HUE14866302A patent/HUE039718T2/hu unknown
- 2014-11-26 ES ES14866302.4T patent/ES2684094T3/es active Active
- 2014-11-26 EP EP14866302.4A patent/EP3073999B1/en active Active
- 2014-11-26 WO PCT/US2014/067586 patent/WO2015081180A1/en active Application Filing
- 2014-11-26 MX MX2016006901A patent/MX363265B/es unknown
- 2014-11-26 AU AU2014354728A patent/AU2014354728B2/en active Active
-
2016
- 2016-05-26 IL IL245865A patent/IL245865B/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
US20170002009A1 (en) | 2017-01-05 |
WO2015081180A1 (en) | 2015-06-04 |
CN104327085B (zh) | 2016-08-24 |
DK3073999T3 (en) | 2018-09-03 |
CN103694241A (zh) | 2014-04-02 |
ES2684094T3 (es) | 2018-10-01 |
HUE039718T2 (hu) | 2019-02-28 |
CN104327085A (zh) | 2015-02-04 |
AU2014354728A1 (en) | 2016-06-16 |
US9751889B2 (en) | 2017-09-05 |
IL245865A0 (en) | 2016-07-31 |
IL245865B (en) | 2019-05-30 |
JP6483126B2 (ja) | 2019-03-13 |
CA2932059A1 (en) | 2015-06-04 |
JP2016538314A (ja) | 2016-12-08 |
MX2016006901A (es) | 2016-10-28 |
PL3073999T3 (pl) | 2018-10-31 |
AU2014354728B2 (en) | 2019-02-28 |
EP3073999A4 (en) | 2017-03-22 |
CA2932059C (en) | 2019-07-02 |
EP3073999B1 (en) | 2018-05-30 |
PT3073999T (pt) | 2018-10-16 |
EP3073999A1 (en) | 2016-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2016006901A (es) | Forma cristalina i de ibrutinib. | |
JOP20190090B1 (ar) | مشتقات 9،8،7،6-رابع هيدرو-3h-بيرازولو [4،3-f]أيزوكينولين مفيدة في علاج السرطان | |
WO2016190683A8 (ko) | 길경 추출물을 함유하는 근육 질환 예방 및 치료용 또는 근 기능 개선용 조성물 | |
PH12017500166A1 (en) | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors | |
PH12016500531A1 (en) | Compound inhibiting activities of btk and/or jak3 kinases | |
EA201590663A1 (ru) | ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА ДЛЯ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ И ДРУГИХ ЗАБОЛЕВАНИЙ | |
EA201691151A1 (ru) | Соединения для лечения пациентов с ros1-мутантными раковыми клетками | |
MX2016004030A (es) | Inhibidores sustituidos de nicotinamida de btk y su preparacion y uso en el tratamiento del cancer, inflamacion y enfermedad autoinmune. | |
NZ703124A (en) | Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide | |
BR112015021888A8 (pt) | inibidores de dna-pk, seus usos e composição farmacêutica | |
NZ631112A (en) | Crystalline bromodomain inhibitors | |
SG10201808104RA (en) | Cenicriviroc for the treatment of fibrosis | |
MX2020012596A (es) | Procesos e intermedios para preparar un medicamento. | |
EA201301353A1 (ru) | Композиции и способы получения пиримидиновых и пиридиновых соединений с втк ингибирующей активностью | |
EA201690093A1 (ru) | Производные пирроло[3,2-d]пиримидина для лечения вирусных инфекций и других заболеваний | |
MY180145A (en) | Cenicriviroc compositions and methods of making and using the same | |
MX2013008296A (es) | Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa. | |
EA201590204A1 (ru) | Твердая композиция, содержащая железо, для применения при железодефицитных состояниях | |
WO2015075561A3 (en) | Crystalline forms of lesinurad and its sodium salt | |
EA201590562A1 (ru) | Бензамиды | |
MX2013002118A (es) | 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3. | |
WO2015071761A3 (en) | Crystalline forms b, c, and d of canagliflozin | |
EA201600318A1 (ru) | Циклические тиеноурацилкарбоксамиды и их применение | |
MX2013002208A (es) | Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes. | |
WO2017168454A3 (en) | Novel compounds as btk inhibitors |